Victoza
Author: Kevin Shannon
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Victoza (liraglutide; Novo Nordisk) is a member of the glucagon-like peptide-1 (GLP-1) agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas. This triggers glucose-dependent insulin secretion, suppressing glucagon secretion, and thereby decreases plasma glucose levels. The major advantage of this class is the associated weight loss, as obesity is a common co-morbidity among type 2 diabetes patients. GLP-1 agonists also delay gastric emptying, thus increasing satiety and suppressing appetite.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Victoza : Diabetes type 2
LIST OF FIGURES
11 Figure 1: Victoza brand franchise for type 2 diabetes – SWOT analysis
12 Figure 2: Datamonitor Healthcare drug assessment of Victoza
13 Figure 3: Datamonitor Healthcare drug assessment scorecard for Victoza
15 Figure 4: Victoza sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
4 Table 1: Victoza drug profile
6 Table 2: Victoza Phase III data in type 2 diabetes
10 Table 3: Difference in key cardiovascular outcomes between Victoza and placebo
16 Table 4: Victoza sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
The Growing Impact of Real-World Evidence 
Sign up to the